Single Cell Analysis Revealed That the Response to Cyclophosphamide Therapy Is Regulated By B Cells in Systemic Sclerosis-Associated Interstitial Lung Disease

被引：0

作者：

Ebata, Satoshi ^{[1
]}

Yoshizaki, Ayumi ^{[2
]}

Fukasawa, Takemichi ^{[1
]}

Nakamura, Kouki ^{[1
]}

Hirakawa, Maiko ^{[1
]}

Yamashita, Takashi ^{[1
]}

Miura, Shunsuke ^{[3
]}

Saigusa, Ryosuke ^{[1
]}

Hirabayashi, Megumi ^{[1
]}

Yoshizaki, Asako ^{[1
]}

Akamata, Kaname ^{[1
]}

Asano, Yoshihide ^{[4
]}

Kazoe, Yutaka ^{[5
]}

Mawatari, Kazuma ^{[5
]}

Kitamori, Takehiko ^{[5
]}

Sato, Shinichi ^{[6
]}

机构：

[1] Univ Tokyo, Grad Sch Med, Dermatol, Tokyo, Japan

[2] Univ Tokyo, Grad Sch Med, Dept Dermatol, Tokyo, Japan

[3] Univ Tokyo, Grad Sch Med, Tokyo, Japan

[4] Univ Tokyo, Grad Sch Med, Appl Chem, Tokyo, Japan

[5] Univ Tokyo, Grad Sch Engn, Appl Chem, Tokyo, Japan

[6] Univ Tokyo, Grad Sch Med, Dept Dermatol, Bunkyo Ku, Tokyo, Japan

来源：

ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：2

共 50 条

[1] B cell infiltration in systemic sclerosis-associated interstitial lung disease
Lafyatis, Robert
O'Hara, Carl
Feghali-Bostwick, Carol A.
Matteson, Eric
ARTHRITIS AND RHEUMATISM, 2007, 56 (09): : 3167 - 3168
[2] B cell cytokine analysis by single cell analysis reveals therapeutic reactivity of systemic sclerosis-associated interstitial lung disease
Yoshizaki, A.
Ebata, S.
Fukasawa, T.
Nakamura, K.
Asano, Y.
Kazoe, Y.
Mawatari, K.
Kitamori, T.
Sato, S.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S8 - S8
[3] Systemic sclerosis-associated interstitial lung disease
Scallan, Ciaran J.
Collins, Bridget F.
Raghu, Ganesh
CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (05) : 487 - 495
[4] Systemic sclerosis-associated interstitial lung disease
Perelas, Apostolos
Silver, Richard M.
Arrossi, Andrea, V
Highland, Kristin B.
LANCET RESPIRATORY MEDICINE, 2020, 8 (03): : 304 - 320
[5] Efficacy of the combined therapy with Rituximab plus Cyclophosphamide versus Cyclophosphamide as Monotherapy in Systemic Sclerosis-Associated Interstitial Lung Disease
Tejeda-Andrade, C. F.
Villalpando-Gomez, Y.
Gamez-Nava, J., I
Castro-Lizano, N.
Rocha-Munoz, A. D.
Cardona, Munoz E. G.
Gonzalez-Lopez, L.
JOURNAL OF RHEUMATOLOGY, 2011, 38 (06) : 1193 - 1193
[6] Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease
Volkmann, Elizabeth R.
Wilhalme, Holly
Tashkin, Donald P.
Kim, Grace Hyun J.
Goldin, Jonathan
Haussmann, Alana
Kuwana, Masataka
Roth, Michael D.
Assassi, Shervin
ARTHRITIS CARE & RESEARCH, 2025,
[7] Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease
Volkmann, Elizabeth
Wilhalme, Holly
Tashkin, Donald
Kim, Grace
Goldin, Jonathan
Haussmann, Alana
Kuwana, Masataka
Roth, Michael
Assassi, Shervin
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3448 - 3449
[8] Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
Bergamasco, Aurore
Hartmann, Nadine
Wallace, Laura
Verpillat, Patrice
CLINICAL EPIDEMIOLOGY, 2019, 11 : 257 - 273
[9] Treatment for systemic sclerosis-associated interstitial lung disease
Roofeh, David
Lescoat, Alain
Khanna, Dinesh
CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (03) : 240 - 248
[10] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Andreasson, Kristofer
Wuttge, Dirk M.
Wollheim, Frank A.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16): : 1595 - 1596

← 1 2 3 4 5 →